{"id":543170,"date":"2021-05-13T18:36:01","date_gmt":"2021-05-13T18:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543170"},"modified":"2021-05-13T18:36:01","modified_gmt":"2021-05-13T18:36:01","slug":"bcell-nonhodgkin-lymphoma-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bcell-nonhodgkin-lymphoma-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis_543170.html","title":{"rendered":"B-Cell Non-Hodgkin Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"B-Cell Non-Hodgkin Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"B-Cell Non-Hodgkin Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;B-Cell Non-Hodgkin Lymphoma Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the B-Cell Non-Hodgkin Lymphoma Market. <\/p>\n<\/div>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The <strong>B-Cell Non-Hodgkin Lymphoma Pipeline<\/strong><\/span><span data-mce-mark=\"1\"><strong> report<\/strong> embraces in-depth <\/span><span data-mce-mark=\"1\">commercial <\/span><span data-mce-mark=\"1\">and clinical assessment of the B-Cell Non-Hodgkin Lymphoma pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <\/span><strong>B-Cell Non-Hodgkin Lymphoma collaborations<\/strong><span data-mce-mark=\"1\">, mergers, acquisition, funding, designations, and other product-related details.<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/b-cell-non-hodgkin-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"B-Cell Non-Hodgkin Lymphoma Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/0dad4fe9b3babf88aa357cf1aa044d49.jpg\" alt=\"B-Cell Non-Hodgkin Lymphoma Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the <strong>B-cell NHL market<\/strong> is anticipated to change in the coming years owing to the launch of emerging therapies during the forecast period. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with B-cell NHL.<\/p>\n<p style=\"text-align: justify;\"><strong>B-Cell Non-Hodgkin Lymphoma Companies:<\/strong><br \/>BeiGene<br \/>Pfizer<br \/>Merck<br \/>AbbVie <br \/>Roche<br \/>Epizyme<br \/>Novartis<br \/>Verastem<br \/>Gilead Sciences<br \/>AstraZeneca<br \/>Merck Sharp &amp; Dohme<br \/>Bristol-Myers Squibb<br \/>Gilead Sciences<br \/>MorphoSys AG<br \/>TG Therapeutics<br \/>Hoffmann-La Roche<br \/>Pharmacyclics <br \/>AbbVie Company<br \/>Celgene Corporation<br \/>Genentech (Roche Group)<br \/>Xynomic Pharmaceuticals<br \/>Spectrum Pharmaceuticals<br \/>Millennium Pharmaceuticals<br \/><strong>And many others.<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>B-Cell Non-Hodgkin Lymphoma Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The report provides insights into:&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The report provides detailed insights about companies that are developing therapies for the <\/span><span data-mce-mark=\"1\">treatment of B-Cell Non-Hodgkin Lymphoma <\/span><span data-mce-mark=\"1\">with aggregate therapies developed by each company for the same.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the B-Cell Non-Hodgkin Lymphoma Treatment.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">B-Cell Non-Hodgkin Lymphoma key companies <\/span><span data-mce-mark=\"1\">involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">B-Cell Non-Hodgkin Lymphoma Drugs<\/span><span data-mce-mark=\"1\"> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the <\/span><span data-mce-mark=\"1\">B-Cell Non-Hodgkin Lymphoma market<\/span><span data-mce-mark=\"1\">.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\"><strong>B-Cell Non-Hodgkin Lymphoma Therapies covered in the report include:<\/strong><br \/>Avelumab<br \/>KTE-X19<br \/>Tafasitamab<br \/>Abexinostat<br \/>Tazemetostat<br \/>Umbralisib<br \/>Lisocabtagene maraleucel<br \/>Brukinsa (Zanubrutinib)<br \/>Polivy (Polatuzumab vedotin)<br \/>Venetoclax (ABT199)<br \/>Kymriah (tisagenlecleucel)<br \/>Copiktra (Duvelisib)<br \/>Imbruvica (Ibrutinib)<br \/>Zydelig (Idelalisib)<br \/>Revlimid (lenalidomide)<br \/>Keytruda (Pembrolizumab)<br \/>Aliqopa (Copanlisib; BAY 80-6946)<br \/>Yescarta (Axicabtagene ciloleucel; KTE-C19)<br \/>Calquence (Acalabrutinib)<br \/>Gazyva (Obinutuzumab, GA-101)<br \/>Velcade (bortezomib)<br \/>And many more.<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Owing to the launch of upcoming therapies, the B-Cell Non-Hodgkin Lymphoma market size shall increase significantly during the forecast period.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of <strong>novel therapeutics for B-Cell Non-Hodgkin Lymphom<\/strong>a.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">In the coming years, the <strong>B-Cell Non-Hodgkin Lymphoma market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The companies and academics are working to assess challenges and seek opportunities that could influence <\/span><strong>B-Cell Non-Hodgkin Lymphoma Research &amp; Development<\/strong><span data-mce-mark=\"1\">. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">A detailed portfolio of major pharma players who are involved in fueling the <\/span><strong>B-Cell Non-Hodgkin Lymphoma treatment market<\/strong><span data-mce-mark=\"1\">. Several potential therapies for B-Cell Non-Hodgkin Lymphoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the B-Cell Non-Hodgkin Lymphoma market size in the coming years.&nbsp;&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Our in-depth analysis of the <\/span><strong>B-Cell Non-Hodgkin Lymphoma pipeline<\/strong><span data-mce-mark=\"1\"><strong> assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">2. B-Cell Non-Hodgkin Lymphoma&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">3. B-Cell Non-Hodgkin Lymphoma Current Treatment Patterns<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">4. B-Cell Non-Hodgkin Lymphoma &#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">5. Therapeutic Assessment<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">6. B-Cell Non-Hodgkin Lymphoma Late Stage Products (Phase-III)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">7. B-Cell Non-Hodgkin Lymphoma Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">12. B-Cell Non-Hodgkin Lymphoma Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">13. B-Cell Non-Hodgkin Lymphoma Product Profiles<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">14. B-Cell Non-Hodgkin Lymphoma Key Companies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">15. B-Cell Non-Hodgkin Lymphoma Key Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">16. Dormant and Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">17. B-Cell Non-Hodgkin Lymphoma Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">18. B-Cell Non-Hodgkin Lymphoma Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">19. B-Cell Non-Hodgkin Lymphoma Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">21. Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/b-cell-non-hodgkin-lymphoma-pipeline-insight<\/a><\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Latest Reports By DelveInsight &#8211;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-non-hodgkin-lymphoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">B-Cell Non-Hodgkin Lymphoma Market<br \/><\/a><\/strong>DelveInsight&rsquo;s &ldquo;B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology and Market Forecast &#8211; 2030&rdquo; report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma Market size and shares analysis for the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/anti-hypertension-market\"><span data-mce-mark=\"1\">Anti-hypertension Market<br \/><\/span><\/a><\/strong>DelveInsight&#8217; s &ldquo;Anti-hypertension Market Insights, Epidemiology, and Market Forecast 2030&rdquo; report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Anti-hypertension market size, share, trends, growth and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bcell-nonhodgkin-lymphoma-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bcell-nonhodgkin-lymphoma-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP &#8220;B-Cell Non-Hodgkin Lymphoma Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the B-Cell Non-Hodgkin Lymphoma Market. The B-Cell Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bcell-nonhodgkin-lymphoma-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis_543170.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-543170","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543170"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543170\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}